Company / Accounts Receivable
Cogent Biosciences, Inc. Accounts Receivable History
FY2017-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$2.0M
FY2019
5-year range
-
FY2017-FY2019
Trend
+19.9%
vs FY2018
Sector context
#102 of 112
Health Care
What the data says
Among 112 Health Care companies, Cogent Biosciences, Inc. is in the bottom 9% for accounts receivable. Improved from $830,000 to $2M over the past 2 years.
Based on SEC 10-K filings.
$2M in FY2019.
Improved from $830,000 to $2M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 9% in Health CareTop 91% of 112This company $2.0M Sector average $1.1B
▼
-99.8% below sector average
Key checks
Key Insights
- In FY2019, accounts receivable increased 19.9% year-over-year.
- Ranks #102 out of 112 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | $2.0M | +19.9% |
| FY2018 | $1.7M | +101.0% |
| FY2017 | $830.0K | - |
As of FY2019 · SEC 10-K · Updated Feb 28, 2026